From: The role of EMMPRIN/CD147 in regulating angiogenesis in patients with psoriatic arthritis
 | Active PsA | Remission PsA | Active RA | Healthy controls | P values, active PsA vs.: | |
---|---|---|---|---|---|---|
Remission PsA | Active RA | |||||
No. participants | 62 | 39 | 33 | 33 | – | – |
Gender: female (%) | 41 (66.1%) | 26 (64.1%) | 26 (78.8%) | 26 (78.8%) | ns3 | ns |
Ethnicity: Jewish | 52 (83.9%) | 39 (100%) | 25 (75.8%) | 30 (90.1%) | 0.0063 | ns |
Age (years) | 56.6 ± 1.8 | 59.13 ± 2.1 | 57.8 ± 1.8 | 58.5 ± 1.7 | ns | ns |
Body mass index (BMI) | 31.26 ± 1.1 | 26.3 ± 0.7 | 29.65 ± 1.1 | 26.9 ± 0.8 | 0.0027 | ns |
Disease duration: arthritis | 12.84 ± 1.4 | 14.1 ± 1.88 | 6.93 ± 0.96 | – | ns | 0.0079 |
Disease duration: psoriasis | 22.79 ± 1.8 | 36.59 ± 2.7 | – | – | < 0.0001 | – |
Tobacco use (%) | 27 (43.5%) | 5 (13.2%) | 13 (39.4%) | 4 (13.3%) | 0.0018 | ns |
Comorbidities | ||||||
 Hypertension | 21 (33.9%) | 11 (28.2%) | 11 (33.3%) | 7 (21.2%) | ns | ns |
 Hyperlipidemia | 27 (43.5%) | 11 (28.2%) | 18 (54.5%) | 9 (27.3%) | ns | ns |
 Diabetes mellitus | 16 (25.8%) | 6 (15.4%) | 9 (27.3%) | 5 (15.2%) | ns | ns |
 Inflammatory bowel disease (IBD) | 2 (3.22%) | 0 (0%) | 0 (0%) | – | ns | ns |
 Thyroid disease | 5 (8.06%) | 2 (5.1%) | 4 (12.1%) | 1 (3.03%) | ns | ns |
 Ischemic heart disease (IHD) | 8 (12.9%) | 0 (0%) | 0 (0%) | 2 (6.1%) | 0.0194 | 0.0311 |
 Cerebrovascular accident (CVA) | 2 (3.2%) | 0 (0%) | 0 (0%) | – | ns | ns |
Medications | ||||||
 None |  |  | 8 (24.2%) | – |  |  |
 cDMARDs1 (total) | 25 (40.3%) | 23 (58.9%) | 23 (69.7%) | – | ns | 0.0094 |
  Methotrexate | 23 (37.1%) | 17 (43.6%) | 20 (60.6%) | – | ns | 0.038 |
  Leflunomide | 4 (6.5%) | 1 (2.6%) | 7 (21.2%) | – | ns | 0.0448 |
  Sulfasalazine | 6 (9.7%) | 7 (17.9%) | – | – | ns | – |
  Hydroxychloroquine | 1 (1.6%) | 0 (0%) | 7 (21.2%) | – | ns | 0.0023 |
 Glucocorticostreroids | 2 (3.2%) | 0 (0%) | 15 (45.4%) | – | ns | < 0.0001 |
 bDMARDs2 (total) | 24 (38.7%) | 17 (43.59%) | 1 (3.0%) | – | ns | < 0.0001 |
 Anti-TNFα agents (total) | 23 (37.1%) | 16 (41.0%) |  | – | ns | 0.0001 |
  Etanercept | 11 (17.7%) | 7 (17.9%) |  | – | ns | – |
  Golimumab | 1 (1.61%) | 2 (5.13%) |  | – | ns | – |
  Adalimumab | 8 (12.9%) | 4 (10.2%) |  | – | ns | – |
  Infliximab | 3 (4.83%) | 3 (7.7%) |  | – | ns | – |
  Abatacept |  |  | 1 (3%) |  |  | – |
 Secukinumab | 2 (3.22%) | 0 (0%) | – | – | ns | – |
 Ustekinumab | 3 (4.83%) | 1 (2.56%) | – | – | ns | – |